Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02576717
Registration number
NCT02576717
Ethics application status
Date submitted
28/09/2015
Date registered
15/10/2015
Date last updated
30/01/2024
Titles & IDs
Public title
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Query!
Scientific title
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Query!
Secondary ID [1]
0
0
RPC01-3001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Sclerosis
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Experimental: 1 mg RPC1063 (Ozanimod) oral capsule - 1 mg RPC1063 (Ozanimod) oral capsule daily
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants Experiencing Adverse Events (AEs)
Query!
Assessment method [1]
0
0
An AE is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product.
Query!
Timepoint [1]
0
0
From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
Query!
Primary outcome [2]
0
0
Number of Participants Experiencing Serious Adverse Events (SAEs)
Query!
Assessment method [2]
0
0
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
Query!
Timepoint [2]
0
0
From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
Query!
Primary outcome [3]
0
0
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
Query!
Assessment method [3]
0
0
An AE is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product.
Query!
Timepoint [3]
0
0
From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
Query!
Primary outcome [4]
0
0
Number of Participants Experiencing Adverse Events (AEs) Leading to Withdrawal
Query!
Assessment method [4]
0
0
An AE is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product.
Query!
Timepoint [4]
0
0
From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
Query!
Primary outcome [5]
0
0
Number of Participants Experiencing Adverse Events (AEs) of Special Interest
Query!
Assessment method [5]
0
0
An AE is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of medicinal product, whether or not considered related to the investigational medicinal product.
Query!
Timepoint [5]
0
0
From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
Query!
Primary outcome [6]
0
0
Number of Participants With Abnormalities in Blood Absolute Lymphocyte Count (ALC)
Query!
Assessment method [6]
0
0
An absolute lymphocyte count (ALC) is a part of a blood test that measures the number of lymphocytes, a type of white blood cell, in the blood. Lymphocytes help fight infections and diseases. Reductions in ALC levels for participants in this study is expected and is a primary pharmacodynamic effect of RPC1063.
LLN = Lower limit of normal
Query!
Timepoint [6]
0
0
From first dose up until last dose of study treatment (up to approximately 82 months)
Query!
Primary outcome [7]
0
0
Number of Participants With Abnormalities in White Blood Cell Count (WBC)
Query!
Assessment method [7]
0
0
A white blood cell count is a part of a blood test that measures the number of white blood cells in the blood. White blood cells help fight infections and diseases.
LLN = Lower limit of normal
Query!
Timepoint [7]
0
0
From first dose up until last dose of study treatment (up to approximately 82 months)
Query!
Primary outcome [8]
0
0
Number of Participants With Abnormalities in Blood Absolute Neutrophil Count (ANC)
Query!
Assessment method [8]
0
0
An absolute neutrophil count is a part of a blood test that measures the number of neutrophils, a type of white blood cell, in the blood. Neutrophils help fight infections and diseases.
Query!
Timepoint [8]
0
0
From first dose up until last dose of study treatment (up to approximately 82 months)
Query!
Primary outcome [9]
0
0
Number of Participants With Abnormalities in Specific Liver Function Tests
Query!
Assessment method [9]
0
0
The number of participants with laboratory abnormalities in specific liver tests above ULN by category. ULN = Upper Limit of Normal
Query!
Timepoint [9]
0
0
From first dose up until last dose of study treatment (up to approximately 82 months)
Query!
Primary outcome [10]
0
0
Number of Participants With Electrocardiogram (ECG) Result Abnormalities
Query!
Assessment method [10]
0
0
An electrocardiogram (ECG) measures electrical activity of the heart to detect cardiac problems.
Query!
Timepoint [10]
0
0
From first dose to 28-days post last dose (an average of 63 months up to a max of 83 months)
Query!
Primary outcome [11]
0
0
Number of Participants With Clinically Relevant Abnormalities in Vital Signs
Query!
Assessment method [11]
0
0
Vital signs included body temperature, sitting heart rate/pulse (HR), sitting systolic blood pressure (SBP), sitting diastolic blood pressure (DBP).
Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [11]
0
0
At baseline and 60 months after first dose of study therapy
Query!
Primary outcome [12]
0
0
Number of Participants With Physical Examination Abnormalities
Query!
Assessment method [12]
0
0
The number of participants with abnormal physical examination results. The assessments included abdominal, extremity, head, heart, lungs, neck, neurological non-MS, other and skin assessments.
Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [12]
0
0
At baseline and every 12 months thereafter up until 84 months post first dose.
Query!
Primary outcome [13]
0
0
Number of Participants Self-Identifying Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)
Query!
Assessment method [13]
0
0
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a unique suicide risk assessment tool that supports suicide risk assessment through a series of simple, plain-language questions. The answers help users identify whether someone is at risk for suicide, assess the severity and immediacy of that risk, and gauge the level of support that the person needs.
Results are displayed as the number of participants who answered "Yes" to at least one of the 10 questions in the suicidal ideation or suicidal behavior section.
Ideation from 1 (wishing to be dead) - 5 (Active suicidal ideation with specific plan and intent) Behavior from 6 (Preparatory acts or behavior) - 10 (Completed suicide). Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [13]
0
0
At baseline and every 3 months thereafter up until 78 months post first dose.
Query!
Primary outcome [14]
0
0
Number of Participants With Changes in Suicidality From Last Day on Treatment Per the Columbia-Suicide Severity Rating Scale (C-SSRS)
Query!
Assessment method [14]
0
0
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a unique suicide risk assessment tool that supports suicide risk assessment through a series of simple, plain-language questions. The answers help users identify whether someone is at risk for suicide, assess the severity and immediacy of that risk, and gauge the level of support that the person needs.
Results are displayed as the number of participants who answered "Yes" to at least one of the 10 questions in the suicidal ideation or suicidal behavior section.
Ideation from 1 (wishing to be dead) - 5 (Active suicidal ideation with specific plan and intent) Behavior from 6 (Preparatory acts or behavior) - 10 (Completed suicide).
Query!
Timepoint [14]
0
0
1, 4, 7, 14, 21, 28, and 90 days post last dose.
Query!
Primary outcome [15]
0
0
Change in Physician's Withdrawal Checklist (PWC-20) Total Score From Last Day on Treatment
Query!
Assessment method [15]
0
0
The PWC-20 is a rater-administered 20-item scale to assess signs and symptoms of withdrawal. Twenty items are rated on a 4-point scale as not present (0 points), mild (1 point), moderate (2 points), or severe (3 points). The points from all items are calculated as a total score. Higher scores indicate more severe withdrawal symptoms.
Query!
Timepoint [15]
0
0
1, 4, 7, 14, 21, and 90 days post last dose.
Query!
Primary outcome [16]
0
0
Change in Hospital Anxiety and Depression Scale (HADS) Score From Last Day on Treatment
Query!
Assessment method [16]
0
0
The HADS is a validated patient reported outcome for assessing anxiety and depression. It consists of 14 items in total, 7 items related to anxiety and 7 items related to depression. For each item patients select a statement (valued at 0 to 3 points) that closest matches their own feeling over the past week. Separate total scores for anxiety and depression are derived by adding up points. Total scores can range from 0 to 21 points. Higher scores indicate more severe anxiety and depression and scores of 8 to 10 are generally considered indicative of borderline anxiety/depression disorders and scores of 11 and higher are generally considered indicative of anxiety/depression disorders.
Query!
Timepoint [16]
0
0
1, 4, 7, 14, 21, and 90 days post last dose.
Query!
Primary outcome [17]
0
0
Changes in Epworth Sleepiness Scale (ESS) Score From Last Day on Treatment
Query!
Assessment method [17]
0
0
The ESS is a validated self administered questionnaire with 8 questions. Respondents rate on a 4-point scale (0 to 3) their chances of dozing off or falling asleep while engaged in 8 different activities. The ESS score is the sum of 8 item scores and can range from 0 to 24 points. Higher scores indicate more daytime sleepiness.
Query!
Timepoint [17]
0
0
1, 4, 7, 14, 21, and 90 days post last dose.
Query!
Primary outcome [18]
0
0
Changes in Vital Sign Values From Last Day on Treatment
Query!
Assessment method [18]
0
0
Vital signs included sitting systolic blood pressure (SBP), sitting diastolic blood pressure (DBP).
Query!
Timepoint [18]
0
0
1, 4, 7, 14, 21, 28, and 90 days post last dose.
Query!
Secondary outcome [1]
0
0
Annualized Relapse Rate (ARR)
Query!
Assessment method [1]
0
0
The Annualized Relapse Rate (ARR) is the average number of relapses per study arm in one year. A relapse is defined as the occurrence of new or worsening neurological symptoms attributable to multiple sclerosis (MS) and immediately preceded by a relatively stable or improving neurological state of at least 30 days. The adjusted ARR was based on the negative binomial regression model with parent treatment group, adjusted for region (Eastern Europe vs Rest of World), age at parent baseline, and the parent baseline number of gadolinium-enhanced (GdE) lesions. The natural log transformation of time on treatment was used as an offset term to adjust for participants having different exposure times.
Query!
Timepoint [1]
0
0
From first dose up until last dose of study treatment or data-cutoff date, whichever occurred first (up to approximately 87 months)
Query!
Secondary outcome [2]
0
0
Time to First Relapse (TFR)
Query!
Assessment method [2]
0
0
The time between first dose of study treatment and first relapse if experienced by a participant. A participant was censored if follow-up ended before a relapse occurred, whether due to the participant completing study, withdrawing from the study, or due to the cutoff of data collection for the analysis. The censor date was the date of the end of study or the date of the data cutoff for participant who were ongoing. Participants who withdrew from the study after the baseline visit were censored at the last known date while on study. Based on Kaplan-Meier product limit estimates.
Query!
Timepoint [2]
0
0
Overall: From first dose to first relapse, last dose, or data-cutoff date, whichever occurred first (up to approx 87 months); Visits: 2 weeks post first dose, 3 months post first dose, and every 3 months thereafter up until 81 months post first dose.
Query!
Secondary outcome [3]
0
0
Number of Participants Who Were Relapse Free
Query!
Assessment method [3]
0
0
The number of participants who did not experience relapse. A relapse is defined as the occurrence of new or worsening neurological symptoms attributable to multiple sclerosis (MS) and immediately preceded by a relatively stable or improving neurological state of at least 30 days.
Query!
Timepoint [3]
0
0
From first dose to last dose of study treatment or data-cutoff date, whichever occurred first (up to approximately 87 months)
Query!
Secondary outcome [4]
0
0
Average Number of New or Enlarging Hyperintense T2-Weighted Brain MRI Lesions Per Scan at Each Visit
Query!
Assessment method [4]
0
0
Adjusted Mean of new enlarging T2 lesions per scan at each visit. Based on a negative binomial regression model, adjusted for parent study, region (Eastern Europe vs. Rest of the World), age at Baseline, and baseline number of GdE lesions.
T2 Magnetic Resonance Imaging (MRI) sequences are used to highlight areas of demyelination in brain neurons, which happens when the outer layer of the neurons is damaged due to multiple sclerosis (MS) activity. T2 sequences can be used to count the total number of MS lesions, which look like bright white spots on T2 sequences, and can be called "hyperintense".
Query!
Timepoint [4]
0
0
At 12 months post first dose and every 12 months thereafter up until 72 months post first dose.
Query!
Secondary outcome [5]
0
0
Average Number of Gadolinium-Enhanced (GdE) Brain MRI Lesions Per Scan at Each Visit
Query!
Assessment method [5]
0
0
Number of gadolinium-enhanced (GdE) (also called GdE enhanced T1) brain MRI lesions per scan at each visit.
Increased numbers of GdE lesions indicates an increase in the in the amount of active inflammation at the site and may be indicative of progressive disease.
Based on a negative binomial regression model, adjusted for parent study, region (Eastern Europe vs. Rest of the World), age at Baseline, and Baseline number of GdE lesions.
Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [5]
0
0
At baseline and every 12 months thereafter up until 72 months post first dose.
Query!
Secondary outcome [6]
0
0
Time to Onset of Disability Progression as Defined by a Sustained Worsening in Expanded Disability Status Scale (EDSS)
Query!
Assessment method [6]
0
0
Multiple sclerosis (MS) disability progression is defined as a sustained worsening in EDSS of 1.0 points or more from baseline, confirmed after a 3-month and 6-month period. The EDSS is a standardized method, widely accepted, numerical scale used to evaluate disability in people with multiple sclerosis (MS). The EDSS is evaluated according to signs and symptoms observed during a standard neurological examination. These clinical observations are classified in 7 FS scales, each of them grading signs and symptoms for different neurological functions: pyramidal, cerebellar, brainstem, sensory, bowel or bladder, visual, and cerebral.
Derived using Kaplan-Meier estimates.
Query!
Timepoint [6]
0
0
At 3 and 6 months post first dose.
Query!
Secondary outcome [7]
0
0
Number of Participants Free of Gadolinium-Enhanced (GdE) Brain Lesions at Each Visit
Query!
Assessment method [7]
0
0
Number of participants without gadolinium enhanced (GdE) brain MRI lesions at each visit. Increased numbers of GdE lesions indicates an increase in the in the amount of active inflammation at the site and may be indicative of progressive disease.
Based on cumulative number of GdE lesions at a participant level.
Query!
Timepoint [7]
0
0
At baseline and every 12 months thereafter up until 72 months post first dose.
Query!
Secondary outcome [8]
0
0
Number of Participants Free of New or Enlarging T2 Lesions at Each Visit
Query!
Assessment method [8]
0
0
Number of participants without new or enlarging T2 brain MRI lesions at each visit. Some multiple Sclerosis (MS) lesions appear as bright spots in a T2-weighted MRI scan - these are called T2 lesions. The presence of new or larger T2 lesions may mean the participant is at higher risk of disability and may have a less favorable long-term outcome.
Based on cumulative number of new or enlarging T2 lesions at a participant level.
Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [8]
0
0
At baseline and every 12 months thereafter up until 72 months post first dose.
Query!
Secondary outcome [9]
0
0
Percent Change in Normalized Brain Volume (Atrophy) on Brain MRI Scans From Baseline at Each Visit
Query!
Assessment method [9]
0
0
Percent change in normalized brain volume (Atrophy) on brain MRI scans from baseline at each visit. Brain atrophy can be seen in the earliest stages of multiple sclerosis (MS) and is a reliable predictor of future physical and cognitive disability.
Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [9]
0
0
At baseline and every 12 months thereafter up until approximately 87 months post first dose.
Query!
Secondary outcome [10]
0
0
Change in Multiple Sclerosis Functional Composite (MSFC) Score From Baseline at Each Applicable Visit
Query!
Assessment method [10]
0
0
The Multiple Sclerosis Functional Composite (MSFC) is a 3-part tool to measure disability progression in those with multiple sclerosis (MS). It assesses leg, arm, hand, and cognitive function using 3 individual scales: - The Timed 25-Foot Walk: To measure leg function - The 9-Hole Peg Test: To measure arm and hand function - The Symbol Digit Modalities Test (SDMT): To measure cognitive processing speed, flexibility, and calculation ability. Scores from each of the three are converted into Z-scores and averaged to create an overall composite score. The Low-Contrast Letter Acuity Test (LCLA) is performed with the MSFC using a set of charts to assess low contrast visual acuity. Each chart corresponds to a different contrast level, and charts are scored based on the number of letters identified correctly. A Z-score of 0 represents the population mean. Standard deviations above the mean represent a better outcome. Baseline refers to assessments on or before receiving study treatment.
Query!
Timepoint [10]
0
0
At baseline and every 12 months thereafter up until 84 months post first dose.
Query!
Secondary outcome [11]
0
0
Change in Multiple Sclerosis Quality of Life 54 Score From Baseline at Each Applicable Visit
Query!
Assessment method [11]
0
0
The Multiple Sclerosis Quality of Life 54 (MSQOL-54) questionnaire is a health-related quality of life (HRQOL) instrument specific for multiple sclerosis (MS). This 54-item instrument generates 12 subscales along with two summary scores (physical health and mental health - derived from a weighted combination of scale scores), and two additional single-item measures. The subscales are: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The MSQOL-54 items are transformed to 0-100 scores, and final scores are obtained by averaging items within the scales. The overall quality of life is assessed in question 54, which is scored on a scale of 0-100. Higher scores indicate better health-related quality of life. Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [11]
0
0
At baseline and every 12 months thereafter up until 84 months post first dose.
Query!
Secondary outcome [12]
0
0
Change From Baseline in Volume of Gadolinium Enhanced T1 Lesions
Query!
Assessment method [12]
0
0
Change from baseline in volume of gadolinium enhanced T1 lesions. T1-lesions are permanently damaged areas of the brain that appear as dark spots or "black holes" on a type of MRI scan. The growth of T1 lesions may mean the participant's Multiple Sclerosis (MS) is progressing.
Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [12]
0
0
At baseline and every 12 months thereafter up until 72 months post first dose.
Query!
Secondary outcome [13]
0
0
Change From Baseline in Volume of T2 Lesions
Query!
Assessment method [13]
0
0
Some multiple Sclerosis (MS) lesions appear as bright spots in a T2-weighted MRI scan - these are called T2 lesions. Larger T2 lesions may mean the participant is at higher risk of disability and may have a less favorable long-term outcome.
Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [13]
0
0
At baseline and every 12 months thereafter up until 72 months post first dose.
Query!
Secondary outcome [14]
0
0
Change From Baseline in Volume of Unenhancing T1 Lesions
Query!
Assessment method [14]
0
0
Change from baseline in volume of unenhancing T1 lesions. T1-lesions are permanently damaged areas of the brain that appear as dark spots or "black holes" on a type of MRI scan. The growth of T1 lesions may mean the participant's Multiple Sclerosis (MS) is progressing.
Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [14]
0
0
At baseline and every 12 months thereafter up until 72 months post first dose.
Query!
Secondary outcome [15]
0
0
Cumulative Number of New Unenhancing T1 Lesions
Query!
Assessment method [15]
0
0
Number of new unenhancing T1 lesions. T1-lesions are permanently damaged areas of the brain that appear as dark spots or "black holes" on a type of MRI scan. The appearance of new T1 lesions may mean the participant's MS is progressing.
Derived as the cumulative number of new or enlarging T1 lesions relative to baseline at a participant level.
Baseline refers to assessments made on or before the first day participants received study treatment.
Query!
Timepoint [15]
0
0
At baseline and every 12 months thereafter up until 72 months post first dose.
Query!
Eligibility
Key inclusion criteria
Eligibility Criteria:
To be eligible to participate in this trial, patients must meet all of the following criteria:
1. Completed one of the parent trials
2. Does not have a condition that would require withdrawal from one of the parent trials
3. Has no conditions requiring treatment with a prohibited concomitant medication
4. Is not receiving treatment with any of the following drugs or interventions within the corresponding timeframe:
At Baseline (Day 1)
* CYP2C8 inhibitors (eg, gemfibrozil or clopidogrel) or inducers (eg, rifampicin) Two weeks prior to Baseline (Day 1)
* Monoamine oxidase inhibitors (eg, selegiline, phenelzine)
5. Ability to provide written informed consent and to be compliant with the schedule of protocol assessments
6. Female patients of childbearing potential:
Must agree to practice a highly effective method of contraception throughout the study until completion of the 90-day Safety Follow-up Visit. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly.
Acceptable methods of birth control in this study are the following:
* Combined hormonal (estrogen and progestogen containing) contraception, which may be oral, intravaginal, or transdermal
* Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, or implantable
* Placement of an intrauterine device (IUD)
* Placement of an intrauterine hormone-releasing system (IUS)
* Bilateral tubal occlusion
* Vasectomised partner
* Sexual abstinence.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/10/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/01/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2494
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Minnesota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Nevada
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Tennessee
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Washington
Query!
Country [11]
0
0
Belarus
Query!
State/province [11]
0
0
Gomel
Query!
Country [12]
0
0
Belarus
Query!
State/province [12]
0
0
Grodno
Query!
Country [13]
0
0
Belarus
Query!
State/province [13]
0
0
Minsk
Query!
Country [14]
0
0
Belarus
Query!
State/province [14]
0
0
Vitebsk
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Brugge
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Bruxelles
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Montegnee
Query!
Country [18]
0
0
Bosnia and Herzegovina
Query!
State/province [18]
0
0
Banja Luka
Query!
Country [19]
0
0
Bosnia and Herzegovina
Query!
State/province [19]
0
0
Sarajevo
Query!
Country [20]
0
0
Bulgaria
Query!
State/province [20]
0
0
Sofia
Query!
Country [21]
0
0
Croatia
Query!
State/province [21]
0
0
Osijek
Query!
Country [22]
0
0
Croatia
Query!
State/province [22]
0
0
Zagreb
Query!
Country [23]
0
0
Estonia
Query!
State/province [23]
0
0
Tallinn
Query!
Country [24]
0
0
Estonia
Query!
State/province [24]
0
0
Tartu
Query!
Country [25]
0
0
Georgia
Query!
State/province [25]
0
0
Tbilisi
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Leipzig
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Potsdam
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Ulm
Query!
Country [29]
0
0
Greece
Query!
State/province [29]
0
0
Athens
Query!
Country [30]
0
0
Greece
Query!
State/province [30]
0
0
Thessaloniki
Query!
Country [31]
0
0
Hungary
Query!
State/province [31]
0
0
Budapest
Query!
Country [32]
0
0
Hungary
Query!
State/province [32]
0
0
Esztergom
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Kistarcsa
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Nyiregyhaza
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Catania
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Cefalu
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Milan
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Montichiari
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Roma
Query!
Country [40]
0
0
Latvia
Query!
State/province [40]
0
0
Riga
Query!
Country [41]
0
0
Lithuania
Query!
State/province [41]
0
0
Kauno Apskritis
Query!
Country [42]
0
0
Lithuania
Query!
State/province [42]
0
0
Klaipeda
Query!
Country [43]
0
0
Moldova, Republic of
Query!
State/province [43]
0
0
Chisinau
Query!
Country [44]
0
0
New Zealand
Query!
State/province [44]
0
0
Christchurch
Query!
Country [45]
0
0
New Zealand
Query!
State/province [45]
0
0
Hamilton
Query!
Country [46]
0
0
Poland
Query!
State/province [46]
0
0
Mazowieckie
Query!
Country [47]
0
0
Poland
Query!
State/province [47]
0
0
Bialystok
Query!
Country [48]
0
0
Poland
Query!
State/province [48]
0
0
Bydgoszcz
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Czeladz
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Gdansk
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Jaroslaw
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Katowice
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Kielce
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Konstancin Jeziorna
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Krakow
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Lublin
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Lódzkie
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Olsztyn
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Plewiska
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Pomorskie
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Poznan
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Rybnik
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Rzeszow
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Szczecin
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Warminsko-mazurskie
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Warsaw
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Warszawa
Query!
Country [68]
0
0
Portugal
Query!
State/province [68]
0
0
Braga
Query!
Country [69]
0
0
Portugal
Query!
State/province [69]
0
0
Coimbra
Query!
Country [70]
0
0
Portugal
Query!
State/province [70]
0
0
Torres Vedras
Query!
Country [71]
0
0
Romania
Query!
State/province [71]
0
0
Brasov
Query!
Country [72]
0
0
Romania
Query!
State/province [72]
0
0
Bucharest
Query!
Country [73]
0
0
Romania
Query!
State/province [73]
0
0
Campulung
Query!
Country [74]
0
0
Romania
Query!
State/province [74]
0
0
Cluj Napoca
Query!
Country [75]
0
0
Romania
Query!
State/province [75]
0
0
Cluj-Napoca
Query!
Country [76]
0
0
Romania
Query!
State/province [76]
0
0
Constanta
Query!
Country [77]
0
0
Romania
Query!
State/province [77]
0
0
Timisoara
Query!
Country [78]
0
0
Serbia
Query!
State/province [78]
0
0
Belgrade
Query!
Country [79]
0
0
Serbia
Query!
State/province [79]
0
0
Kragujevac
Query!
Country [80]
0
0
Serbia
Query!
State/province [80]
0
0
Nis
Query!
Country [81]
0
0
Slovakia
Query!
State/province [81]
0
0
Bratislava
Query!
Country [82]
0
0
Slovakia
Query!
State/province [82]
0
0
Lucenec
Query!
Country [83]
0
0
Slovakia
Query!
State/province [83]
0
0
Trnava
Query!
Country [84]
0
0
South Africa
Query!
State/province [84]
0
0
Pretoria
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Barcelona
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Bilbao
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Girona
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Madrid
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Majadahonda
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Pamplona/ Navarra
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
San Sebastian
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Sant Joan Despí
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Sevillla
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Valencia
Query!
Country [95]
0
0
Sweden
Query!
State/province [95]
0
0
Goteborg
Query!
Country [96]
0
0
Ukraine
Query!
State/province [96]
0
0
Cherkasy
Query!
Country [97]
0
0
Ukraine
Query!
State/province [97]
0
0
Chernihiv
Query!
Country [98]
0
0
Ukraine
Query!
State/province [98]
0
0
Chernivtsi
Query!
Country [99]
0
0
Ukraine
Query!
State/province [99]
0
0
Dnipropetrovsk
Query!
Country [100]
0
0
Ukraine
Query!
State/province [100]
0
0
Ivano Frankivsk
Query!
Country [101]
0
0
Ukraine
Query!
State/province [101]
0
0
Ivano-Frankivsk
Query!
Country [102]
0
0
Ukraine
Query!
State/province [102]
0
0
Kharkiv
Query!
Country [103]
0
0
Ukraine
Query!
State/province [103]
0
0
Kherson
Query!
Country [104]
0
0
Ukraine
Query!
State/province [104]
0
0
Kyiv
Query!
Country [105]
0
0
Ukraine
Query!
State/province [105]
0
0
Lutsk
Query!
Country [106]
0
0
Ukraine
Query!
State/province [106]
0
0
Lviv
Query!
Country [107]
0
0
Ukraine
Query!
State/province [107]
0
0
Odesa
Query!
Country [108]
0
0
Ukraine
Query!
State/province [108]
0
0
Poltava
Query!
Country [109]
0
0
Ukraine
Query!
State/province [109]
0
0
Uzhhorod
Query!
Country [110]
0
0
Ukraine
Query!
State/province [110]
0
0
Vinnytsia
Query!
Country [111]
0
0
Ukraine
Query!
State/province [111]
0
0
Zaporizhia
Query!
Country [112]
0
0
Ukraine
Query!
State/province [112]
0
0
Zaporizhzhia
Query!
Country [113]
0
0
Ukraine
Query!
State/province [113]
0
0
Zaporizhzhya
Query!
Country [114]
0
0
Ukraine
Query!
State/province [114]
0
0
Zhytomyr
Query!
Country [115]
0
0
United Kingdom
Query!
State/province [115]
0
0
East Sussex
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Inverness
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Celgene
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02576717
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/17/NCT02576717/Prot_SAP_000.pdf
Statistical analysis plan
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/17/NCT02576717/Prot_SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT02576717
Download to PDF